Seqens Seqens

X
[{"orgOrder":0,"company":"Scipher Medicine","sponsor":"Galapagos","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Scipher Medicine and Galapagos Sign Collaboration in Inflammatory Bowel Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"August 2020","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Discovery"},{"orgOrder":0,"company":"Scipher Medicine","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Scipher Medicine Signs Multi-Target Partnership with Ionis","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform"}]

Find Clinical Drug Pipeline Developments & Deals by Scipher Medicine

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Under the collaboration, Ionis will be responsible for advancing, developing and commercializing oligonucleotide therapies directed to targets discovered by Scipher’s Spectra™ platform.

            Lead Product(s): Oligonucleotide Therapy

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Large molecule

            Partner/Sponsor/Collaborator: Ionis Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration July 17, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Scipher and Galapagos will jointly validate a suite of novel IBD targets discovered by Scipher after which Galapagos has the exclusive option to progress up to five targets into further drug discovery and development.

            Lead Product(s): Undisclosed

            Therapeutic Area: Gastroenterology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Galapagos

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration August 12, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY